Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50


Co-culture with lung cancer A549 cells promotes the proliferation and migration of mesenchymal stem cells derived from bone marrow.

Zhang YM, Zhang ZM, Guan QL, Liu YQ, Wu ZW, Li JT, Su Y, Yan CL, Luo YL, Qin J, Wang Q, Xie XD.

Exp Ther Med. 2017 Oct;14(4):2983-2991. doi: 10.3892/etm.2017.4909. Epub 2017 Aug 8.


Genetically engineered mouse models of melanoma.

Pérez-Guijarro E, Day CP, Merlino G, Zaidi MR.

Cancer. 2017 Jun 1;123(S11):2089-2103. doi: 10.1002/cncr.30684. Review.


p53 targets TSPAN8 to prevent invasion in melanoma cells.

Agaësse G, Barbollat-Boutrand L, El Kharbili M, Berthier-Vergnes O, Masse I.

Oncogenesis. 2017 Apr 3;6(4):e309. doi: 10.1038/oncsis.2017.11.


AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.

de Polo A, Luo Z, Gerarduzzi C, Chen X, Little JB, Yuan ZM.

J Mol Cell Biol. 2017 Apr 1;9(2):154-165. doi: 10.1093/jmcb/mjw045.


Current State of Animal (Mouse) Modeling in Melanoma Research.

Kuzu OF, Nguyen FD, Noory MA, Sharma A.

Cancer Growth Metastasis. 2015 Oct 6;8(Suppl 1):81-94. doi: 10.4137/CGM.S21214. eCollection 2015. Review.


Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination.

Herraiz C, Calvo F, Pandya P, Cantelli G, Rodriguez-Hernandez I, Orgaz JL, Kang N, Chu T, Sahai E, Sanz-Moreno V.

J Natl Cancer Inst. 2015 Oct 13;108(1). pii: djv289. doi: 10.1093/jnci/djv289. Print 2016 Jan.


Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A.

Cancer Res. 2015 Jan 1;75(1):181-93. doi: 10.1158/0008-5472.CAN-14-2405. Epub 2014 Nov 14.


Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment.

Coleman DJ, Chagani S, Hyter S, Sherman AM, Löhr CV, Liang X, Ganguli-Indra G, Indra AK.

Mol Cancer Res. 2015 Jan;13(1):186-96. doi: 10.1158/1541-7786.MCR-14-0164. Epub 2014 Sep 4.


Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.

Johnson DB, Smalley KS, Sosman JA.

Clin Cancer Res. 2014 Aug 15;20(16):4186-92. doi: 10.1158/1078-0432.CCR-13-3270. Epub 2014 Jun 3. Review.


Melanoma: from melanocyte to genetic alterations and clinical options.

Bertolotto C.

Scientifica (Cairo). 2013;2013:635203. doi: 10.1155/2013/635203. Epub 2013 Dec 12. Review.


Skin Tumors Rb(eing) Uncovered.

Costa C, Paramio JM, Santos M.

Front Oncol. 2013 Dec 17;3:307. doi: 10.3389/fonc.2013.00307. Review.


The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression.

Liu Y, Sánchez-Tilló E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Postigo A, Dean DC.

J Biol Chem. 2014 Feb 14;289(7):4116-25. doi: 10.1074/jbc.M113.533505. Epub 2013 Dec 26.


Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma.

Yuan X, He J, Sun F, Gu J.

Int J Clin Exp Pathol. 2013 Nov 15;6(12):2651-67. eCollection 2013.


Genetics of melanoma.

Wangari-Talbot J, Chen S.

Front Genet. 2013 Jan 25;3:330. doi: 10.3389/fgene.2012.00330. eCollection 2012.


Reconstructing skin cancers using animal models.

Gober MD, Bashir HM, Seykora JT.

Cancer Metastasis Rev. 2013 Jun;32(1-2):123-8. doi: 10.1007/s10555-012-9410-8. Review.


NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Fedorenko IV, Gibney GT, Smalley KS.

Oncogene. 2013 Jun 20;32(25):3009-18. doi: 10.1038/onc.2012.453. Epub 2012 Oct 15. Review.


Ribosomal stress, p53 activation and the tanning response.

Walker G, Box N.

Expert Rev Dermatol. 2008 Dec;3(6):649-656.


GAB2 induces tumor angiogenesis in NRAS-driven melanoma.

Yang Y, Wu J, Demir A, Castillo-Martin M, Melamed RD, Zhang G, Fukunaga-Kanabis M, Perez-Lorenzo R, Zheng B, Silvers DN, Brunner G, Wang S, Rabadan R, Cordon-Cardo C, Celebi JT.

Oncogene. 2013 Aug 1;32(31):3627-37. doi: 10.1038/onc.2012.367. Epub 2012 Aug 27.


MDM4 is a key therapeutic target in cutaneous melanoma.

Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC.

Nat Med. 2012 Aug;18(8):1239-47. doi: 10.1038/nm.2863. Epub 2012 Jul 22.


Melanoma: from mutations to medicine.

Tsao H, Chin L, Garraway LA, Fisher DE.

Genes Dev. 2012 Jun 1;26(11):1131-55. doi: 10.1101/gad.191999.112. Review.

Supplemental Content

Support Center